- Home
- » Tags
- » Targeted therapy
Top View
- Effective Combinatorial Immunotherapy for Penile Squamous Cell Carcinoma
- The Legally Binding Text Is the Original French Version TRANSPARENCY COMMITTEE OPINION 2 February 2011 VOTRIENT 200 Mg, Film-Coa
- Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer Funda Meric-Bernstam1,2,3, Amber M
- Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: Another Paradigm Shift?
- Venetoclax-Based Therapies for Acute Myeloid Leukemia T ∗ Veronica A
- Current State of Target Treatment in BRAF Mutated Melanoma
- As an Inhibitor of KSHV Driven Primary Effusion Lymphoma Via Disruption of Mitochondrial OXPHOS Metabolism
- Ado-Trastuzumab Emtansine for the Adjuvant Treatment of HER2
- Combinatory Therapy Targeting Mitochondrial Oxidative
- Excellent Outcomes Reported for First Targeted Therapy for Pediatric Hodgkin Lymphoma 8 April 2021
- Press Release
- Longitudinal Trends in Use and Costs of Targeted Therapies for Common Cancers in Taiwan: a Retrospective Observational Study
- Clinical Use of Tyrosine Kinase Inhibitors: Therapy for Chronic Myelogenous Leukemia and Other Cancers
- DRUG NAME: Bevacizumab
- My Journey from Tyrosine Phosphorylation Inhibitors to Targeted Immune Therapy As Strategies to INAUGURAL ARTICLE Combat Cancer
- Capture of Systemic Anticancer Therapy Use by Routinely Collected Health Datasets
- Statistical Analysis Plan
- Targeted Therapy and the T315I Mutation in Philadelphia-Positive Leukemias
- Bevacizumab in the Treatment of Non-Small-Cell Lung Cancer
- Deep and Sustained Response After Venetoclax Therapy in a Patient With
- Ado-Trastuzumab Emtansine (KADCYLA) Drug Monograph
- Treatment: Systemic Therapy: Hormonal Therapy and Targeted Agents
- Review of Venetoclax in CLL, AML and Multiple Myeloma
- Targeted Therapy How Targeted Therapies Are Used to Treat Cancer
- Targeting HER2 with Trastuzumab Deruxtecan: a Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- This Thesis Has Been Submitted in Fulfilment of the Requirements for a Postgraduate Degree (E.G
- Targeted Cancer Therapy Foreword
- Review Article Imatinib: a Breakthrough of Targeted Therapy in Cancer
- Treatment Patterns and Survival in HER2-Positive Early Breast Cancer: a Whole-Of-Population Australian Cohort Study (2007–2016)
- Venetoclax Fact Sheet
- Versus Single-Agent HER2 Inhibition and Incidence of Intracranial
- Original Article Systematic Screen with Kinases Inhibitors Reveals Kinases Play Distinct Roles in Growth of Osteoprogenitor Cells
- The Changing Paradigm for the Treatment of HER2-Positive Breast Cancer
- How I Manage Chronic Lymphocytic Leukemia
- Understanding Targeted Therapy a Guide for People Affected by Cancer
- Understanding Targeted Therapy a Guide for People Affected by Cancer
- Brentuximab Vedotin Plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III Or IV Hodgkin Lymphoma Radhakrishnan Ramchandren1, Ranjana H
- Incorporation of Brentuximab Vedotin in the Treatment of Lymphoma: Current Evidence and Potential Use in Indonesia
- Personalized Healthcare in Oncology: Past, Present and Future
- Lessons for Solid Tumors from Chronic Myelogenous Leukemia Therapy
- Corporate Medical Policy BRAF Gene Mutation Testing to Select Melanoma Or Glioma Patients for Targeted Therapy
- Brentuximab Vedotin
- Oral Targeted Therapy for Cancer
- Real-World Experience with Targeted Therapy in BRAF Mutant Advanced
- Anti-CD30 Chimeric Antigen Receptor T Cell Therapy for Relapsed/Refractory CD30+ Lymphoma Patients D
- Cardiovascular Toxicity of Tyrosine Kinase Inhibitors Used in Chronic Myeloid Leukemia: an Analysis of the FDA Adverse Event Reporting System Database (FAERS)
- Immunotherapy Or Molecularly Targeted Therapy: What Is the Best Initial Treatment for Stage IV BRAF-Mutant Melanoma? Geoffrey T
- Novel Therapies and Approaches to Relapsed/Refractory HL Beyond Chemotherapy
- Targeted Therapy in CLL: Changing the Treatment Paradigm
- Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
- Ibrutinib Combinations in CLL Therapy: Scientific Rationale and Clinical Results
- BRAF Targeted Therapy After Immunotherapy for Patients with Metastatic Melanoma: a Review of Clinical Effectiveness
- Targeted Therapy Treatment
- Monoclonal Antibodies in Cancer Therapy
- Targeted Therapies: a New Generation of Cancer Treatments DAVID E
- TARGETED THERAPY Targeted Therapy Treats Cancer at Its Most Basic Biological Level
- Targeted Therapy in Leukemia
- (T-DM1) As Adjuvant Treatment of HER2-Positive Early Breast Cancer: Safety and Efficacy
- Kadcyla (Trastuzumab Emtansine) and Notanother Trastuzumab-Containing Product (E.G
- Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
- (DS-8201A) in Subjects with HER2-Low Expressing Breast Cancer
- Dan Liang, Pharmd Associate Director, Medical Information & Education Daiichi Sankyo, Inc
- Mitogen-Activated Protein Kinase Pathway and the Scaffolding Protein PTPIP51
- Precision Medicine in Oncology: Understanding Targeted Therapy and Biopsies Understanding Targeted Therapies
- Product Monograph
- Targeted Therapy for Lung Cancer
- Breast Cancer
- Risk Assessment and Risk Mitigation Review(S)
- Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors